Literature DB >> 23988169

Electrophysiological effects of bosentan in rats with induced cerebral ischemia-reperfusion.

Bekir Akgun1, Metin Kaplan, Caner F Demir, Aysel Sarı, Hasan H Ozdemir, Said M Berilgen.   

Abstract

We examined the effect of bosentan, an ETA and ETB receptor antagonist, on EEG, an indicator of neuronal activity, in rats with experimentally induced cerebral ischemia-reperfusion. The rats were divided into three groups with seven rats in each group. Before the procedures, the EEGs of all rats were recorded for ten minutes. 30 mg/kg bosentan in 2 cc physiological serum was administered to the first group, and the second and third groups were injected with 2 cc physiological serum intraperitoneally. After the administration, the right and the left common carotid arteries of the animals in Groups 1 and 2 were clipped for 10 minutes using aneurysm clippings. The rats in the third group received only a subcutaneous incision. Ten minutes after the clips were removed in the first and second groups and after the incision in the third group, EEG recordings were repeated for 10 minutes. All the rats were decapitated and MDA values in the brain tissue were measured for evaluation of the efficiency of induced cerebral ischemia. Induced cerebral ischemia was performed effectively because the MDA levels in Groups 1 and 2 were elevated, compared to the levels in Group 3 (p<0.05). After the application of the Cerebral Ischemia-Reperfusion Technique, the EEG showed minimal slowing in the rats in Group 1, and generalized diffuse slowing in the rats in Group 2 compared to pre-ischemic findings. Bosentan may reduce the damage induced by ischemia on neuronal electrophysiology, likely through its vasodilation effect on cerebral vessels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23988169      PMCID: PMC4333983          DOI: 10.17305/bjbms.2013.2358

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  20 in total

1.  Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke.

Authors:  Y Lampl; G Fleminger; R Gilad; R Galron; I Sarova-Pinhas; M Sokolovsky
Journal:  Stroke       Date:  1997-10       Impact factor: 7.914

Review 2.  Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia.

Authors:  Pak H Chan
Journal:  Neurochem Res       Date:  2004-11       Impact factor: 3.996

Review 3.  Reactive oxygen radicals in signaling and damage in the ischemic brain.

Authors:  P H Chan
Journal:  J Cereb Blood Flow Metab       Date:  2001-01       Impact factor: 6.200

Review 4.  Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology.

Authors:  B K Siesjö
Journal:  J Neurosurg       Date:  1992-08       Impact factor: 5.115

Review 5.  Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Free Radic Biol Med       Date:  2005-11-21       Impact factor: 7.376

6.  Study of endothelin-1 in acute ischemic stroke.

Authors:  Violeta Sapira; Inimioara Mihaela Cojocaru; Gabriela Lilios; M Grigorian; M Cojocaru
Journal:  Rom J Intern Med       Date:  2010

7.  Lactacidosis modulates glutathione metabolism and oxidative glutamate toxicity.

Authors:  Jan Lewerenz; Richard Dargusch; Pamela Maher
Journal:  J Neurochem       Date:  2010-01-28       Impact factor: 5.372

8.  Endothelins in health and disease.

Authors:  Rahman Shah
Journal:  Eur J Intern Med       Date:  2007-07       Impact factor: 4.487

9.  High-dose bosentan in the prevention and treatment of subarachnoid hemorrhage-induced cerebral vasospasm: an open-label feasibility study.

Authors:  Raul G Nogueira; Michael J Bodock; Walter J Koroshetz; Mehmet A Topcuoglu; Bob S Carter; Christopher S Ogilvy; Johnny C Pryor; Ferdinando S Buonanno
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

10.  Quantitative EEG correlates of low cerebral perfusion in severe stroke.

Authors:  Jennifer Diedler; Marek Sykora; Thomas Bast; Sven Poli; Roland Veltkamp; Patricio Mellado; Thorsten Steiner; André Rupp
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.